Company filings, made visual.

Find a company. Follow its revenue through costs and profit.

Market

Find a company or ticker

Coverage includes separate ticker and security records; counts are not unique companies.

The Cooper Companies, Inc.

COO

Filing: SEC 10-Q
Period: Three months ended March 31, 2026
Basis: Editorial filing; Read original SEC 10-Q ↗

Sankey diagram of The Cooper Companies, Inc.. A complete text table follows the diagram.

The Cooper Companies Combines Vision Care and Surgical Products

CooperVision and CooperSurgical create two complementary healthcare product platforms.

Swipe to explore

Source & review

Read original SEC 10-Q ↗

SEC accession: 0001628280-26-041305
Filed: Date not recorded
Reviewed: Date not recorded
Status: Individual filing review complete

How to read these figures

Labels and displayed flow values are reported filing values or exact disclosed subtotals.

Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.

The filing reports $1,081.5M net sales; CooperVision is disclosed at $723.5M and the surgical node is the exact residual.

View accessible tables

Financial categories · Three months ended March 31, 2026 · Millions of USD
Category	Stage	Value	Notes
The Cooper Companies revenue	1	$1.1B	$1,081.5M reported quarterly revenue
Vision care platform	2	$724M	Reported segment net sales
Surgical platform	2	$358M	Exact residual to consolidated net sales

Financial flows · Millions of USD
From	To	Value
The Cooper Companies revenue	Vision care platform	$724M
The Cooper Companies revenue	Surgical platform	$358M